Printer Friendly

LYME DISEASE VACCINE PROVEN SAFE AND EFFECTIVE; USDA GRANTS FIRST FEDERAL LICENSE TO CANINE PRODUCT

 LYME DISEASE VACCINE PROVEN SAFE AND EFFECTIVE;
 USDA GRANTS FIRST FEDERAL LICENSE TO CANINE PRODUCT
 WASHINGTON, July 8 /PRNewswire/ -- The United States Department of Agriculture (USDA) has granted the first full federal license for a canine Lyme disease vaccine. The inoculation that protects dogs has been approved as safe and effective.
 According to the USDA analysis, field performance evaluations of the product in Lyme disease endemic areas over the last 20 months have shown that Fort Dodge Laboratories' LymeVax(TM) vaccine is safe and that vaccinated dogs are eight times less likely to exhibit clinical symptoms of Lyme disease than non-vaccinated dogs. These findings are part of a presentation to be given at an upcoming conference on tick-borne diseases in September in St. Paul, Minn.
 "While the world waits for a human vaccine, dog owners can now have their pet vaccinated against this debilitating disease," said Dr. Steven A. Levy, one of the veterinarians who conducted the field tests on the canine vaccine. "Dogs are six to 10 times more likely to catch Lyme disease than are humans because they are much more likely to be exposed to tick bites."
 The five-year development of the canine vaccine is detailed in two articles scheduled to be published in the August 1992 issue of The Journal of the American Veterinary Medical Association. One of the articles describes how Fort Dodge Laboratories scientists were the first known researchers to re-create the clinical signs of Lyme disease in a laboratory setting. This breakthrough was pivotal to the development and testing of an effective vaccine.
 Subsequently, this challenge model has been successfully duplicated in research laboratories at the University of Georgia, the company said.
 The second article describes the laboratory testing and effectiveness of the canine vaccine. The vaccine contains chemically inactivated whole organisms of Borrelia burgdorferi, the bacterium that causes Lyme disease. The Fort Dodge product has both Osp (outer surface protein) A and Osp B antigens, which have been shown in previously reported scientific literature to stimulate the most protective immunity against experimental Lyme disease.
 In addition, the article describes how the Fort Dodge vaccine protects against B. burgdorferi organisms found in areas throughout the country. This was shown in research used to challenge the vaccine which used Lyme disease organisms from a different geographical location of the United States than the organism used to make the vaccine. The vaccine proved effective in these tests.
 According to the authors, this indicates the vaccine is capable of stimulating a cross-protective immunity in vaccinated dogs against different strains of Lyme disease.
 -0- 7/8/92
 /CONTACT: Wm. E. Ryan, D.V.M., Fort Dodge Laboratories, 515-955-4600; or Tim Riesterer of The Brady Co., 414-255-0100, for Fort Dodge Laboratories/ CO: Fort Dodge Laboratories; United States Department of Agriculture ST: Iowa, District of Columbia IN: MTC SU: PDT


ML -- DE003 -- 7290 07/08/92 09:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 8, 1992
Words:480
Previous Article:AT&T OFFERS CALLING PROMOTION TO CELEBRATE BASTILLE DAY
Next Article:MICHCON OFFERS $5,000 REWARD IN BUSINESS OFFICE ROBBERY
Topics:


Related Articles
CONNAUGHT LABORATORIES' LYME DISEASE VACCINE ENTERS PHASE THREE CLINICAL TRIALS
THERION BIOLOGICS RECEIVES $5.0 MIL. GRANT FROM NIAID TO EXPAND AIDS VACCINE DEVELOPMENT PROGRAM; HARVARD LICENSEE RECEIVES $6.0 MIL. GRANT
DOG LYME DISEASE VACCINE MAY ALSO STOP NEW TRANSMISSION THREAT
CAMBRIDGE BIOTECH REPORTS AUDITED FINANCIAL RESULTS FOR 1995
Cambridge Biotech Corporation Reports Financial Results For The Second Quarter 1996
Aquila QS-21 Adjuvant Key Component of Promising Malaria Vaccine Reported in The New England Journal of Medicine
Clinical Trial Demonstrates Pasteur Merieux Connaught's Candidate Lyme Disease Vaccine Reduces Overall Occurrence of Lyme Disease in Participants
Clinical Trial Demonstrates Pasteur Merieux Connaught's Candidate Lyme Disease Vaccine Reduces Overall Occurrence of Lyme Disease in Participants
Clinical Results With AVANT Rotavirus Vaccine Demonstrate Nearly 90% Protection in Young Children.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters